[go: up one dir, main page]

MX2019005251A - Animales no humanos geneticamente modificados y metodos de uso de los mismos. - Google Patents

Animales no humanos geneticamente modificados y metodos de uso de los mismos.

Info

Publication number
MX2019005251A
MX2019005251A MX2019005251A MX2019005251A MX2019005251A MX 2019005251 A MX2019005251 A MX 2019005251A MX 2019005251 A MX2019005251 A MX 2019005251A MX 2019005251 A MX2019005251 A MX 2019005251A MX 2019005251 A MX2019005251 A MX 2019005251A
Authority
MX
Mexico
Prior art keywords
methods
genetically modified
modified non
human animals
human
Prior art date
Application number
MX2019005251A
Other languages
English (en)
Other versions
MX385035B (es
Inventor
J Murphy Andrew
Manz Markus
Stevens Sean
A Flavell Richard
Rongvaux Anthony
Willinger Tim
Yancopoulos George
Strowig Till
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2019005251A publication Critical patent/MX2019005251A/es
Publication of MX385035B publication Critical patent/MX385035B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5403—IL-3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0387—Animal model for diseases of the immune system

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

En general, la invención se refiere a animales no humanos genéticamente modificados que expresan polipéptidos humanos y sus métodos de uso.
MX2019005251A 2012-09-07 2013-09-06 Animales no humanos geneticamente modificados y metodos de uso de los mismos. MX385035B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261698002P 2012-09-07 2012-09-07
US201361775171P 2013-03-08 2013-03-08
PCT/US2013/058448 WO2014039782A2 (en) 2012-09-07 2013-09-06 Genetically modified non-human animals and methods of use thereof

Publications (2)

Publication Number Publication Date
MX2019005251A true MX2019005251A (es) 2019-08-05
MX385035B MX385035B (es) 2025-03-14

Family

ID=50237767

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015002983A MX364714B (es) 2012-09-07 2013-09-06 Animales no humanos geneticamente modificados y metodos de uso de los mismos.
MX2019005251A MX385035B (es) 2012-09-07 2013-09-06 Animales no humanos geneticamente modificados y metodos de uso de los mismos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015002983A MX364714B (es) 2012-09-07 2013-09-06 Animales no humanos geneticamente modificados y metodos de uso de los mismos.

Country Status (18)

Country Link
US (6) US9820476B2 (es)
EP (3) EP2892330B1 (es)
JP (5) JP6283031B2 (es)
KR (7) KR102340059B1 (es)
CN (4) CN108782459B (es)
AU (3) AU2013312359B8 (es)
CA (1) CA2881468C (es)
DK (1) DK2892330T3 (es)
ES (2) ES3034290T3 (es)
FI (1) FI2892330T3 (es)
IL (4) IL307969B1 (es)
IN (1) IN2015DN02032A (es)
MX (2) MX364714B (es)
NZ (3) NZ746089A (es)
PT (1) PT2892330T (es)
RU (2) RU2768282C2 (es)
SG (2) SG10201701759VA (es)
WO (1) WO2014039782A2 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2591107T3 (es) 2009-10-06 2016-11-24 Regeneron Pharmaceuticals, Inc. Ratones modificados genéticamente e injerto
SG192606A1 (en) 2011-02-15 2013-09-30 Regeneron Pharma Humanized m-csf mice
RU2768282C2 (ru) 2012-09-07 2022-03-23 Йель Юниверсити Генетически модифицированные не принадлежащие к человеческому роду животные и способ их использования
ES2748662T3 (es) * 2012-11-05 2020-03-17 Institute For Res In Biomedicine Irb Roedores inmunodeficientes modificados genéticamente y métodos de uso de los mismos
TR201901782T4 (tr) 2013-09-23 2019-03-21 Regeneron Pharma İnsanlaştirilmiş bi̇r si̇nyal düzenleyi̇ci̇ protei̇n geni̇ne sahi̇p olan i̇nsan dişi hayvanlar.
MX2016004781A (es) 2013-10-15 2016-07-26 Regeneron Pharma Il-15 humanizada en animales.
MY183189A (en) 2013-11-19 2021-02-18 Regeneron Pharma Non-human animals having a humanized a proliferation-inducing ligand gene
SG10202003996YA (en) 2014-05-05 2020-06-29 Regeneron Pharma Humanized c5 and c3 animals
NO2785538T3 (es) 2014-05-07 2018-08-04
PT3145307T (pt) 2014-05-19 2019-04-08 Univ Yale Animais não humanos geneticamente modificados que expressam epo humana
SG11201703463WA (en) 2014-12-05 2017-05-30 Regeneron Pharma Non-human animals having a humanized cluster of differentiation 47 gene
CN113412818B (zh) 2014-12-09 2022-11-04 瑞泽恩制药公司 具有人源化分化簇274基因的非人动物
CN107249318A (zh) 2014-12-10 2017-10-13 明尼苏达大学董事会 用于治疗疾病的遗传修饰的细胞、组织和器官
US10123518B2 (en) * 2015-04-13 2018-11-13 Regeneron Pharmaceuticals, Inc Genetically modified non-human animals and methods of use thereof
RS61866B1 (sr) 2015-11-20 2021-06-30 Regeneron Pharma Ne-humane životinje koje imaju humanizovani gen za aktivaciju limfocita 3
US10582702B2 (en) 2016-02-04 2020-03-10 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered ANGPTL8 gene
ES2886958T3 (es) 2016-02-29 2021-12-21 Regeneron Pharma Roedores que tienen un gen TMPRSS humanizado
CN106119284A (zh) * 2016-06-27 2016-11-16 北京维通达生物技术有限公司 一种用于构建免疫缺陷动物模型的产品及其应用
WO2018102546A1 (en) * 2016-11-30 2018-06-07 The Jackson Laboratory Humanized mouse model with improved human innate immune cell development
US11778994B2 (en) * 2017-05-12 2023-10-10 The Jackson Laboratory NSG mice lacking MHC class I and class II
US11589562B2 (en) 2018-07-16 2023-02-28 Regeneran Pharmaceuticals, Inc. Mouse model of DITRA disease and uses thereof
US20210355501A1 (en) * 2018-09-24 2021-11-18 Albert Einstein College Of Medicine Interleukin-8 for maintenance of human acute myeloid leukemia and myelodysplastic syndrome and uses thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN111073907B (zh) * 2018-12-25 2025-07-29 百奥赛图江苏基因生物技术有限公司 人源化细胞因子csf1基因改造非人动物的构建方法及应用
CN111118019B (zh) * 2018-12-25 2021-03-16 百奥赛图江苏基因生物技术有限公司 人源化细胞因子il3基因改造非人动物的构建方法及应用
WO2021011853A2 (en) * 2019-07-17 2021-01-21 Yale University Genetically modified non-human animals and methods of use thereof
WO2021083366A1 (en) * 2019-11-01 2021-05-06 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with human or chimeric thpo
US11339279B2 (en) * 2020-04-01 2022-05-24 Chevron Phillips Chemical Company Lp Dual catalyst system for producing LLDPE and MDPE copolymers with long chain branching for film applications
WO2022222958A1 (en) * 2021-04-20 2022-10-27 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric genes
IL318159A (en) 2022-07-19 2025-03-01 Regeneron Pharma Genetically modified animal model and its use to model the human immune system
AU2024304358A1 (en) 2023-06-16 2025-11-06 Regeneron Pharmaceuticals, Inc. Vectors, genetically modified cells, and genetically modified non-human animals comprising the same
US20250255282A1 (en) 2024-02-08 2025-08-14 Regeneron Pharmaceuticals, Inc. Vectors, genetically modified cells, and genetically modified non-human animals comprising the same
WO2025212991A1 (en) 2024-04-05 2025-10-09 Regeneron Pharmaceuticals, Inc. Rodent models of disease

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4736866A (en) 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
US5573930A (en) 1985-02-05 1996-11-12 Cetus Oncology Corporation DNA encoding various forms of colony stimulating factor-1
HU215241B (hu) 1986-10-24 1998-11-30 Cetus Corp. Eljárás telepstimuláló faktor-1 új formáinak előállítására, valamint az eljárásban alkalmazható expressziós kazetta, vektor és rekombináns gazdasejtek előállítására
ATE119197T1 (de) 1987-12-23 1995-03-15 Univ Leland Stanford Junior Schimäre immunkompromittierende säugetiere und ihre verwendung.
JP2981486B2 (ja) 1988-06-14 1999-11-22 メディカル・バイオロジー・インスティチュート 哺乳動物の免疫系研究方法
US5652373A (en) 1990-01-15 1997-07-29 Yeda Research And Development Co. Ltd. Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems
US5849288A (en) 1990-01-15 1998-12-15 Yeda Research And Development Co. Ltd. Method for production of monoclonal antibodies in chimeric mice or rats having xenogeneic antibody-producing cells
EP0438053B1 (en) 1990-01-15 1999-06-16 Yeda Research And Development Company Limited Durable engraftment and development of human hematopoietic lineages in normal mammals
ATE140480T1 (de) 1990-05-03 1996-08-15 Systemix Inc Menschliches lymph-gewebe in einem wirt mit angegriffenem immunsystem
US5633426A (en) 1990-05-25 1997-05-27 Systemix, Inc. In vivo use of human bone marrow for investigation and production
CA2064075A1 (en) 1990-05-25 1991-11-26 Charles M. Baum Human peripheral blood cells in an immunocompromised host
AU1419292A (en) 1991-02-11 1992-09-07 Ayub K. Ommaya Spinal fluid driven artificial organ
US5222982A (en) 1991-02-11 1993-06-29 Ommaya Ayub K Spinal fluid driven artificial organ
EP0517199A1 (en) 1991-06-04 1992-12-09 Yeda Research And Development Company, Ltd. Durable engraftment of human tissue and cells in normal mammals
WO1993005796A1 (en) 1991-09-19 1993-04-01 The Scripps Research Institute Method for producing human antibodies in a non-human animal, and animals therefor
EP0539970B1 (en) 1991-10-30 1999-05-26 Idemitsu Kosan Company Limited Methods for producing human lymphocytes and human monoclonal antibodies, and human monoclonal antibodies produced thereby
US6353150B1 (en) 1991-11-22 2002-03-05 Hsc Research And Development Limited Partnership Chimeric mammals with human hematopoietic cells
WO1993018144A1 (en) 1992-03-05 1993-09-16 The Trustees Of Columbia University Of The City Of New York Recombination activating gene deficient animal
US5866757A (en) 1992-06-02 1999-02-02 Yeda Research And Development Co. Ltd. Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems
US6018096A (en) 1993-05-03 2000-01-25 Surrogen, Inc. Animal model for engraftment, proliferation and differentiation of human hematopoietic stem cells
CA2103693A1 (en) 1993-08-06 1995-02-07 Steven Gallinger Animal model of the human immune system
EP0771348A1 (en) 1994-07-27 1997-05-07 Merck & Co. Inc. Bradykinin b2 receptor modified transgenic non-human animals
US6455756B1 (en) 1994-08-12 2002-09-24 Novartis Ag Long term xenogeneic myeloid and lymphoid cell production in chimeric immunocompromised mice
US7273753B2 (en) 1996-08-02 2007-09-25 Center Of Blood Research Purification and uses of dendritic cells and monocytes
JP4312265B2 (ja) 1997-04-09 2009-08-12 ラング−ジ チャン ワクチン評価のための動物モデル
US6248721B1 (en) 1997-04-09 2001-06-19 Lung-Ji Chang Method of using mouse model for evaluation of HIV vaccines
US20030028911A1 (en) 1999-08-31 2003-02-06 Manley Huang Transgenic mammal capable of facilitating production of donor-specific functional immunity
AU7340000A (en) 1999-08-31 2001-03-26 Genencor International, Inc. Transgenic mammal capable of facilitating production of donor-specific functional immunity
JP2004500810A (ja) 1999-12-09 2004-01-15 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド Ｉｌ−６様ポリヌクレオチド、ポリペプチド、および抗体
AU2001290855A1 (en) 2000-09-14 2002-03-26 Genetrol Biotherapeutics, Inc. Method and cell composition for screening compounds for anti-inflammatory activity
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DE60238486D1 (de) * 2001-07-10 2011-01-13 Johnson & Johnson Res Pty Ltd Verfahren zur genetischen modifikation hämatopoetischer vorläuferzellen und verwendungen der modifizierten zellen
AU2002363322A1 (en) 2001-10-26 2003-05-19 Large Scale Biology Corporation Endothelial cell derived hemotopoietic growth factor
EP1994824A1 (en) 2001-11-15 2008-11-26 Kirin Pharma Kabushiki Kaisha Chimeric non-human animal
WO2004005496A1 (ja) 2002-07-05 2004-01-15 Kirin Beer Kabushiki Kaisha 臍帯血、骨髄、末梢血等に含まれる新規な未分化幹細胞集団
CN101250553A (zh) 2002-07-13 2008-08-27 上海医学遗传研究所 一种促人血小板生成素表达载体及其构建方法
US20040128703A1 (en) 2002-09-09 2004-07-01 Hiroaki Shizuya Methods and compositions for the generation of humanized mice
EP1418185A1 (en) 2002-11-11 2004-05-12 Aventis Pharma Deutschland GmbH Use of EDG2 receptor in an animal model of heart failure
EP1573314B1 (en) 2002-12-16 2008-07-23 Genentech, Inc. Transgenic mice expressing human cd20
PL2767161T3 (pl) 2004-10-19 2018-09-28 Regeneron Pharmaceuticals, Inc. Sposób wytwarzania zwierzęcia homozygotycznego pod względem modyfikacji genetycznej
US7759541B2 (en) 2004-12-13 2010-07-20 Iti Life Sciences Transgenic animals for assessing drug metabolism and toxicity
GB2434578A (en) 2006-01-26 2007-08-01 Univ Basel Transgenic animals
DK2019683T4 (da) 2006-04-25 2022-08-29 Univ California Indgivelse af vækstfaktorer til behandling af CNS-lidelser
EP1878342A1 (en) 2006-07-13 2008-01-16 Institut Pasteur Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses
WO2008060360A2 (en) 2006-09-28 2008-05-22 Surmodics, Inc. Implantable medical device with apertures for delivery of bioactive agents
WO2008069659A1 (en) 2006-12-05 2008-06-12 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Improved xenogenic immune system in a non-human mammal
AU2008262487B2 (en) 2007-05-23 2013-10-31 Sangamo Therapeutics, Inc. Methods and compositions for increased transgene expression
GB0718029D0 (en) 2007-09-14 2007-10-24 Iti Scotland Ltd Two step cluster deletion and humanisation
WO2009042917A1 (en) 2007-09-28 2009-04-02 The General Hospital Corporation Methods and compositions for antibody production
JP2011500005A (ja) * 2007-10-11 2011-01-06 ユニバーシティー ヘルス ネットワーク ヒト造血幹細胞の生着を増加させるためのＳＩＲＰα−ＣＤ４７相互作用の調節およびそのための化合物
US8521273B2 (en) 2008-01-29 2013-08-27 Gilbert H. KLIMAN Drug delivery devices, kits and methods therefor
JP2012531894A (ja) * 2009-06-29 2012-12-13 レスコフ，イリヤ，ビー． ヒト血液癌の非ヒト哺乳動物モデル
CN102725400A (zh) * 2009-06-29 2012-10-10 麻省理工学院 制造人源化的非人类哺乳动物的方法
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
ES2591107T3 (es) 2009-10-06 2016-11-24 Regeneron Pharmaceuticals, Inc. Ratones modificados genéticamente e injerto
EP2618656B1 (en) 2010-09-20 2018-06-20 Yale University, Inc. HUMAN SIRPalpha TRANSGENIC ANIMALS AND THEIR METHODS OF USE
WO2012051572A1 (en) 2010-10-15 2012-04-19 Massachusetts Institute Of Technology A humanized non-human mammal model of malaria and uses thereof
SG192606A1 (en) 2011-02-15 2013-09-30 Regeneron Pharma Humanized m-csf mice
HUE033400T2 (en) 2011-10-28 2017-12-28 Regeneron Pharma Humanized IL-6 and IL-6 receptor
RU2768282C2 (ru) 2012-09-07 2022-03-23 Йель Юниверсити Генетически модифицированные не принадлежащие к человеческому роду животные и способ их использования
ES2748662T3 (es) 2012-11-05 2020-03-17 Institute For Res In Biomedicine Irb Roedores inmunodeficientes modificados genéticamente y métodos de uso de los mismos
TR201901782T4 (tr) 2013-09-23 2019-03-21 Regeneron Pharma İnsanlaştirilmiş bi̇r si̇nyal düzenleyi̇ci̇ protei̇n geni̇ne sahi̇p olan i̇nsan dişi hayvanlar.
MX2016004781A (es) 2013-10-15 2016-07-26 Regeneron Pharma Il-15 humanizada en animales.
PT3145307T (pt) 2014-05-19 2019-04-08 Univ Yale Animais não humanos geneticamente modificados que expressam epo humana
US10123518B2 (en) 2015-04-13 2018-11-13 Regeneron Pharmaceuticals, Inc Genetically modified non-human animals and methods of use thereof

Also Published As

Publication number Publication date
AU2021240324A1 (en) 2021-10-28
AU2021240324B2 (en) 2024-02-22
CA2881468C (en) 2023-03-21
US11026408B2 (en) 2021-06-08
JP2022105531A (ja) 2022-07-14
NZ741951A (en) 2020-04-24
MX385035B (es) 2025-03-14
KR102241962B1 (ko) 2021-04-20
KR102473555B1 (ko) 2022-12-05
AU2013312359B8 (en) 2019-08-15
MX2015002983A (es) 2015-06-17
EP2892330A4 (en) 2016-07-27
KR20150052274A (ko) 2015-05-13
ES3034290T3 (en) 2025-08-14
US20180020647A1 (en) 2018-01-25
US20210368752A1 (en) 2021-12-02
IL307969B1 (en) 2025-10-01
EP2892330B1 (en) 2022-11-23
KR102645622B1 (ko) 2024-03-11
IL282472B2 (en) 2024-04-01
CN108782459B (zh) 2021-11-05
SG11201500504RA (en) 2015-02-27
RU2642319C2 (ru) 2018-01-24
RU2017145913A (ru) 2019-02-19
CN113897398A (zh) 2022-01-07
KR102340059B1 (ko) 2021-12-17
IL282472B1 (en) 2023-12-01
JP7066785B2 (ja) 2022-05-13
AU2013312359A1 (en) 2015-02-19
WO2014039782A3 (en) 2015-07-23
US10433527B2 (en) 2019-10-08
RU2017145913A3 (es) 2021-08-16
RU2015112607A (ru) 2016-10-27
SG10201701759VA (en) 2017-04-27
US12127537B2 (en) 2024-10-29
KR20230153500A (ko) 2023-11-06
EP4193834C0 (en) 2025-05-14
FI2892330T3 (fi) 2023-03-25
KR102287541B1 (ko) 2021-08-10
JP2015529083A (ja) 2015-10-05
AU2013312359B2 (en) 2019-05-23
HK1211176A1 (en) 2016-05-20
US20150208622A1 (en) 2015-07-30
US20250072405A1 (en) 2025-03-06
RU2768282C2 (ru) 2022-03-23
CN120718856A (zh) 2025-09-30
CN108782459A (zh) 2018-11-13
IN2015DN02032A (es) 2015-08-14
EP4193834B1 (en) 2025-05-14
JP6517958B2 (ja) 2019-05-22
IL282472A (en) 2021-06-30
EP4606818A3 (en) 2025-10-22
CN104955326B (zh) 2018-07-20
NZ704957A (en) 2018-05-25
PT2892330T (pt) 2023-02-17
JP7605789B2 (ja) 2024-12-24
WO2014039782A2 (en) 2014-03-13
EP4193834A1 (en) 2023-06-14
KR20210044315A (ko) 2021-04-22
JP6732998B2 (ja) 2020-07-29
US9820476B2 (en) 2017-11-21
JP2018088925A (ja) 2018-06-14
ES2938342T3 (es) 2023-04-10
IL307969A (en) 2023-12-01
EP4606818A2 (en) 2025-08-27
US20190082663A1 (en) 2019-03-21
NZ746089A (en) 2020-05-29
EP2892330A2 (en) 2015-07-15
IL236877A0 (en) 2015-03-31
IL265570A (en) 2019-05-30
KR102594390B1 (ko) 2023-10-27
JP2020168024A (ja) 2020-10-15
MX364714B (es) 2019-05-06
CN113897398B (zh) 2025-07-08
JP2019110922A (ja) 2019-07-11
DK2892330T3 (da) 2023-01-30
IL265570B (en) 2021-05-31
CA2881468A1 (en) 2014-03-13
KR20240045263A (ko) 2024-04-05
US20200093105A1 (en) 2020-03-26
AU2013312359A8 (en) 2019-08-15
KR20210156846A (ko) 2021-12-27
AU2019216625B2 (en) 2021-07-08
KR20220164808A (ko) 2022-12-13
KR20210099664A (ko) 2021-08-12
CN104955326A (zh) 2015-09-30
AU2019216625A1 (en) 2019-09-05
JP6283031B2 (ja) 2018-02-21

Similar Documents

Publication Publication Date Title
MX2019005251A (es) Animales no humanos geneticamente modificados y metodos de uso de los mismos.
IL290613A (en) Humanized or chimeric cd3 antibodies
IL272325B (en) Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
CO6680644A2 (es) Polipétidos de ralaxina modificados y sus usos
CL2018000457A1 (es) Anticuerpos anti-mesotelina completamente humanos y células con efecto inmune dirigido a la mesotelina
CR20150618A (es) Anticuerpos receptores de antitransferina y métodos de uso
DK2838548T3 (en) Hla class ii deficient cells, hla class i deficient cells capable of expressing hla class ii proteins, and uses thereof
MX2017007585A (es) Anticuerpos anti-c10orf54 y usos de los mismos.
UY34782A (es) Anticuerpos humanos para fel d1 y métodos para usarlos.
UY34484A (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
BR112015003149A2 (pt) células natural killer e usos das mesmas.
CL2014002954A1 (es) Composicion farmaceutica que contiene anticuerpos anti-il-23p19 y sus usos.
AU343911S (en) Animal garment
EP3918974C0 (en) DETERMINATION OF ASTIGMATISM AND REFRACTION BY COMPUTER
PL2922875T3 (pl) Przeciwciała anty-CEACAM5 i ich zastosowanie
UY34721A (es) Anticuerpos anti-hla-b*27 y usos de éstos.
UY4234Q (es) Configuración aplicada en zapato
ECSP12012105A (es) Antídotos de Anticoagulantes
BR112014000049A2 (pt) pirrolotriazinas substituídas com hidroximelilarilo e sua utilização
HRP20181398T1 (hr) Specifična antitijela za amiloid polipeptida humanih otočića (hiapp) i njegova upotreba
CU24405B1 (es) Proteínas de variantes de secuencias de aminoácidos de cry1da1 activas para lepidópteros
CO7020877A2 (es) Anticuerpos anti-asic1 y usos de los mismos
BR112015002610A2 (pt) modelo animal de obesidade e métodos de sua fabricação e uso
BR112015021707A2 (pt) uso de células de planta que expresam um inibidor de polipeptídeo tnfalfa em terapia.
UY34590A (es) Fenilimidazopirazoles sustituidos y su uso